These results collectively demonstrate that underexpression of TNFRSF4, as observed in our cisplatin-resistance model, is associated with adverse clinical outcomes in neuroblastoma as well as poor prognostic indicators. This evidence concerns the gene TNFRSF4 and neuroblastoma.